In our ongoing conversation with James Cancer Hospital’s Don M. Benson, MD, PhD, he explains his philosophy of always striving to deliver personalized patient care.
Continuing our discussion with The Ohio State University Comprehensive Cancer Center’s Don M. Benson, MD, PhD, hematologist-oncologist, he explains how he navigates the intricacies of conversations with patients when quality-of-life preferences may conflict with treatment goals, always keeping patient preferences top of mind. One of Benson’s top priorities it to always deliver personalized patient care by taking into account their specific type of cancer and their desires and goals for treatment.
For parts 1 through 3 of our conversation with Benson, please click on the links below:
Part 1: Elevating Myeloma Care Amidst Complex Treatment Choices
Part 2: Balancing Life and Myeloma: A Patient-Centered Approach
Part 3: Unlocking Myeloma Outcomes: The Role of Immunity
This transcript has been lightly edited for clarity.
Transcript
When patients choose quality of life over continuing treatment, how do you navigate those conversations?
There was a wonderful study published a few years ago where they looked at patient expectations as a function of where they were in the journey of their myeloma disease. It's striking, because at diagnosis, their number 1 goal—in this paper anyway—was overall survival. Nothing else mattered. And in the relapse/refractory setting, the number 1 goal, by far and away, was survival. The reason it's such an interesting paper is that that middle, that in-between, when the disease is in remission, it's all about quality of life. It's energy, fatigue, pain, cognitive function, independence, freedom. Those metrics take on substantially more meaning and importance for patients overall and beyond survival.
Myeloma is not a sprint, it's a marathon. And I think as physicians, as specialists, we need to be sensitive to where patients are in the journey. When somebody is newly diagnosed, their risk tolerance is very different than when their disease is in remission and you're trying to cajole them into taking a maintenance pill that might cause diarrhea or it might cause a rash. This is what I mean by taking into account patients' desires and goals.
I'll give you another example. We had a patient last year who was diagnosed in the early part of the year, got induction treatment, got into remission, we collected his stem cells, and then his daughter got engaged. And she wanted to get married while dad was well. The wedding was in October, and he came in and said, “I want to walk my daughter down the aisle with a full head of hair and I want to dance at her reception with a full head of hair.” And so we delayed his transplant.
That's sort of what I mean by tailoring treatment to individuals. And he's doing great, by the way; he got a transplant, he's killing it, he's doing awesome.
I can tell you with great confidence that I've taken so much more from my patients than I could ever give them. When you're confronted with your mortality and being told you have an incurable cancer, I'm truly humbled to walk into… I hesitate to even call it work. It's just a privilege to come in and be with these people. And in some way, if I can help them, that's great. But they've taught me so much more about how to live and how to love and how to sacrifice and what life really means.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More